Time to activate lung cancer clinical trials and patient enrollment: A representative comparison study between two academic centers across the atlantic

Journal of Clinical Oncology

Volumn 28, Issue 24, 2010, Pages 3803-3807

  Wang Gillam, Andrea ^a   Williams, Kristina ^a   Novello, Silvia ^a   Gao, Feng ^a   Scagliotti, Giorgio V ^a   Govindan, Ramaswamy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CENTER; EUROPE; HUMAN; LUNG CANCER; METHODOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; UNITED STATES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; ITALY; LUNG TUMOR; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PUBLISHING; RETROSPECTIVE STUDY; TIME; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG INDUSTRY; HUMANS; ITALY; JOURNALISM, MEDICAL; LUNG NEOPLASMS; PATIENT SELECTION; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 77956247583     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.1824     Document Type: Article

References (13)

1. Go RS, Frisby KA, Lee JA, et al: Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 106:426-433, 2006 (Pubitemid 43100454)
2. DeVita VT Jr: The clinical trials system is broken. Nat Clin Pract Oncol 5:683, 2008
3. Dilts DM, Sandler A, Cheng S, et al: Development of clinical trials in a cooperative group setting: The Eastern Cooperative Oncology Group. Clin Cancer Res 14:3427-3433, 2008
4. Dilts DM, Sandler AB: Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 24:4545-4552, 2006 (Pubitemid 46630949)
5. Dilts DM, Sandler AB, Baker M, et al: Processes to activate phase III clinical trials in a cooperative oncology group: The case of Cancer and Leukemia Group B. J Clin Oncol 24:4553-4557, 2006 (Pubitemid 46630950)
6. American Society of Clinical Oncology: American Society of Clinical Oncology policy statement: Oversight of clinical research. J Clin Oncol 21:2377-2386, 2003
7. Wagner TH, Murray C, Goldberg J, et al: Costs and benefits of the National Cancer Institute Central Institutional Review Board. J Clin Oncol 28:662-666, 2010
8. Mello MM, Clarridge BR, Studdert DM: Academic medical centers' standards for clinical-trial agreements with industry. N Engl J Med 352:2202-2210, 2005 (Pubitemid 40727087)
9. Glickman SW, McHutchison JG, Peterson ED, et al: Ethical and scientific implications of the globalization of clinical research. N Engl J Med 360:816-823, 2009
10. Dilts D, Sandler AB: Activating and opening oncology clinical trials: process and timing analysis. Presented at Institute of Medicine National Cancer Policy Forum, Multi-site Clinical Trials and the NCI Cooperative Group Program: A Workshop, Washington, DC, July 1-2, 2008
11. Lara PN Jr, Higdon R, Lim N, et al: Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 19:1728-1733, 2001 (Pubitemid 32230874)
12. Hagler KT, Lynch JW Jr: Potential influence of health systems in accrual to clinical trials in lymphoma. J Clin Oncol 23:7244-7245, 2005
13. Shah S: Globalization of clinical research by the pharmaceutical industry. Int J Health Serv 33:29-36, 2003